GRAN® / Peglasta® / Neulasta®

GRAN® (Filgrastim) is a human colony-stimulating factor (G-CSF) produced by genetic recombination technology. It works to selectively increase the count of a type of white blood cell called neutrophil, as well as increase their functional efficacy. This enables a quick recovery from neutropenia occurring as a result of cancer chemotherapy and reduces the risk of infection, allowing for more effective chemotherapy. It also acts to relieve congenital neutropenia or neutropenia occurring after hematopoietic stem-cell transplantation (such as bone-marrow transplants). It received additional approval for application to PBSCT (peripheral blood stem cell transfusion) mobilization as well.

In Asia, Kyowa Kirin have marketed pegfilgrastim as G-LASTA® /Peglasta® /Neulasta® for chemotherapy-induced febrile neutropenia.

Neulasta® is a registered trademark of Amgen Inc.

This page features main products from Kyowa Kirin worldwide portfolio and may not be available in all countries or regions, or may be approved for different indications, in different dosages, or in different strengths. In general, those products are available only by prescription through local healthcare professionals.
Please visit our local country or region website for local information:

Go to your country or region website